Zai Lab (ZLAB), buoyed by a strong start in the first quarter of the 2024, expects to accelerate commercial performance for the remainder of the year.
This research-based, commercial-stage biopharmaceutical company, based in China and the United States, has five marketed products - Zejula, Optune, Qinlock, Nuzyra, and Vyvgart - that have been commercially launched in one or more territories in Greater China.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com